Hannah Anderson
February 9, 2026
Washington, D.C.—Today, the America First Policy Institute released an expert insight analyzing the affordability benefits of the TrumpRx drug discount program and how it can benefit American patients.
“TrumpRx is patients-first policymaking, ending the pharmacy counter surprise and putting affordability and transparency back where they belong. By giving Americans a direct path to the lowest possible price, we can expand access to breakthrough treatments like GLP-1s and help more families afford the care that keeps them healthy,” said Hannah Anderson, Director of Healthy America Policy and Senior Director of Policy.
“Under the Great Health Care Plan, the Trump Administration is giving Americans more of their health dollars. This combination—Trump Rx, the end of global freeloading, plus the discount through a Health Savings Account (HSA)—drastically drives down the cost of drugs, something that no other Administration has been able to do. As an example, many patients use GLP-1 medications to help lower blood sugar and regulate appetite. Some patients could pay up to $1,300 for this medication. But when using Trump Rx and an HSA, the price of one GLP-1, Wegovy, will drop from $1,300 a month to an average of $226 a month. This is even lower for those patients who get health dollars directly from their employers, on average, at $160 a month. That’s a discount of up to 88%. This is tremendous progress towards ending global freeloading and putting patients first,” continued Anderson.
This program will not just affect Americans today, but for years to come as more drugs become directly available at discounted prices that allow patients more choice and competition in where they get their prescription drugs. Americans deserve to be healthy again, and TrumpRx is an affordable solution to that important mission.
Read the full AFPI brief here.